Genomictree Inc. (228760.KQ)
KRW 23550.0
(3.06%)
KRW 23550.0
(3.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.41 Billion KRW | -88.56% |
| 2022 | 29.86 Billion KRW | 481.09% |
| 2021 | 5.13 Billion KRW | 314.87% |
| 2020 | 1.23 Billion KRW | 339.89% |
| 2019 | 281.62 Million KRW | -27.22% |
| 2018 | 386.94 Million KRW | -14.69% |
| 2017 | 453.55 Million KRW | -17.28% |
| 2016 | 548.33 Million KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 284.69 Million KRW | -56.98% |
| 2024 Q2 | 559.78 Million KRW | 96.62% |
| 2023 Q1 | 1.16 Billion KRW | -29.27% |
| 2023 Q4 | 661.71 Million KRW | 24.35% |
| 2023 FY | 3.41 Billion KRW | -88.56% |
| 2023 Q2 | 1.05 Billion KRW | -9.17% |
| 2023 Q3 | 532.15 Million KRW | -49.73% |
| 2022 Q2 | 1.05 Billion KRW | -95.81% |
| 2022 FY | 29.86 Billion KRW | 481.09% |
| 2022 Q4 | 1.64 Billion KRW | -14.37% |
| 2022 Q3 | 1.92 Billion KRW | 82.19% |
| 2022 Q1 | 25.23 Billion KRW | 865.96% |
| 2021 FY | 5.13 Billion KRW | 314.87% |
| 2021 Q3 | 168.21 Million KRW | 0.0% |
| 2021 Q4 | 2.61 Billion KRW | 1453.18% |
| 2020 FY | 1.23 Billion KRW | 339.89% |
| 2019 FY | 281.62 Million KRW | -27.22% |
| 2018 FY | 386.94 Million KRW | -14.69% |
| 2017 FY | 453.55 Million KRW | -17.28% |
| 2016 FY | 548.33 Million KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | 92.033% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | 64.342% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 97.792% |
| Bioneer Corporation | 263.23 Billion KRW | 98.702% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | 47.417% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 95.021% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | 29.94% |
| Helixmith Co., Ltd | 4.2 Billion KRW | 18.65% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 99.642% |
| Medy-Tox Inc. | 221.12 Billion KRW | 98.454% |
| Peptron, Inc. | 3.34 Billion KRW | -2.278% |
| Amicogen, Inc. | 159.9 Billion KRW | 97.862% |
| Genexine, Inc. | 4.42 Billion KRW | 22.785% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 93.641% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | 89.99% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 96.459% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 98.69% |
| SillaJen, Inc. | 3.93 Billion KRW | 13.239% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 94.179% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | 79.97% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | 81.699% |
| EASY BIO,Inc. | 165.38 Billion KRW | 97.933% |
| GI Innovation, Inc. | 5.31 Billion KRW | 35.738% |